SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

BioSig Technologies, Inc. – ‘8-K’ for 1/14/20

On:  Friday, 1/17/20, at 9:47am ET   ·   For:  1/14/20   ·   Accession #:  1185185-20-50   ·   File #:  1-38659

Previous ‘8-K’:  ‘8-K’ on / for 12/31/19   ·   Next:  ‘8-K’ on / for 2/19/20   ·   Latest:  ‘8-K’ on 3/18/24 for 3/12/24   ·   11 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/17/20  BioSig Technologies, Inc.         8-K:8,9     1/14/20    3:49K                                    Federal Filings, LLC/FA

Current Report   —   Form 8-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     14K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     12K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML      9K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:  <>  <> 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 14, 2020

 

BioSig Technologies, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

001-38659

26-4333375

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

  

Identification No.)

 

54 Wilton Road, 2nd Floor

Westport, Connecticut

  

06880

(Address of principal executive offices)

  

(Zip Code)

 

(310)-620-9320

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 Securities registered pursuant to Section 12(b) of the Act:

 

 

 

 

 

 

Title of each class

 

Trading Symbol(s)

 

Name of exchange on which registered

Common Stock, par value $0.001 per share

 

BSGM

 

The NASDAQ Capital Market  

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 8.01                      Other Events.

 

On January 14, 2020, BioSig Technologies, Inc. (the “Company”) issued a press release announcing that the Company has been awarded a fifth utility patent covering its PURE EP™ System. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

On January 16, 2020, the Company issued a press release announcing that it installed its PURE EP™ System at Mayo Clinic in Florida (the “Clinic”) to conduct patient cases under the Company’s clinical trial titled “Novel Cardiac Signal Processing System for Electrophysiology Procedures (PURE EP 2.0 Study).” A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein.

 

Item 9.01             Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number

 

Description

99.1   Press Release, dated January 14, 2020

99.2

 

Press Release, dated January 16, 2020

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BIOSIG TECHNOLOGIES, INC.

 

 

Date: January 17, 2020                                  By:  /s/ Kenneth L. Londoner                

Name: Kenneth L. Londoner 

Title: Executive Chairman

 

 

 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:1/17/20None on these Dates
1/16/20
For Period end:1/14/20
 List all Filings 


11 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/13/23  BioSig Technologies, Inc.         424B5                  1:504K                                   M2 Compliance LLC/FA
 9/15/23  BioSig Technologies, Inc.         424B5                  1:382K                                   Federal Filings, LLC/FA
 8/18/23  BioSig Technologies, Inc.         424B5                  1:369K                                   Federal Filings, LLC/FA
 6/28/22  BioSig Technologies, Inc.         424B5                  1:445K                                   Federal Filings, LLC/FA
 6/23/22  BioSig Technologies, Inc.         424B5                  1:460K                                   Federal Filings, LLC/FA
 5/17/22  BioSig Technologies, Inc.         424B5                  1:364K                                   Federal Filings, LLC/FA
 3/22/22  BioSig Technologies, Inc.         424B5                  1:355K                                   Federal Filings, LLC/FA
 7/06/21  BioSig Technologies, Inc.         424B5                  1:451K                                   Federal Filings, LLC/FA
 7/01/21  BioSig Technologies, Inc.         424B5                  1:443K                                   Federal Filings, LLC/FA
12/31/20  BioSig Technologies, Inc.         S-3                    3:357K                                   Federal Filings, LLC/FA
 8/28/20  BioSig Technologies, Inc.         424B5                  1:482K                                   Federal Filings, LLC/FA
Top
Filing Submission 0001185185-20-000050   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 4:18:39.2am ET